Skip navigation
7th Annual Clinical Data Disclosure, Transparency & Dissemination promo banner
Patient Registries, Real World Evidence and HEOR promo banner
Medicare Pricing & Contracting Congress promo banner
PAP 2020 – 21st Annual Patient Assistance and Access Programs promo banner

FDA Approves Amgen Drug for Acute Lymphoblastic Leukemia

Amgen's bispecific T-cell engager (BiTE) antibody constructs help the body fight malignant cancer cells.
Published Date: 
December 3, 2014
URL: 
http://www.biopharminternational.com/biopharm/Biologics/FDA-Approves-Amgen-Drug-for-Acute-Lymphoblastic-Le/ArticleStandard/Article/detail/862680?contextCategoryId=435&ref=25
Title: 
FDA Approves Amgen Drug for Acute Lymphoblastic Leukemia
Short Description: 
Amgen's bispecific T-cell engager (BiTE) antibody constructs help the body fight malignant cancer cells.